rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients

Table 2

Demographic and biochemical characteristics of the study groups.

	Group 1 (𝑛=42); (lower viscosity)	Group 2 (𝑛=42); (hyperviscosity)	𝑃 value
Age	55.4±14.8	54.3±12.5	0.728
HD duration (months)	97.5±83.1	133.2±77.1	0.044
PTH (pg/mL)	492.3±500.3	562±436	0.498
Calcium (Ca) (mg/dL)	9.1±0.6	9.5±0.6	0.009
Phosphor (P) (mg/dL)	4.7±1	5.1±0.8	0.035
Ca × P	43.4±11.4	49.3±9.3	0.011
Albumin (g/dL)	3.7±0.3	3.5±0.3	0.171
URR (%)	69.4±5.8	71.7±6.1	0.079
Hb (g/dL)	11.4±1.7	11.1±1.3	0.439
Platelet (/µL)	221.8±66.4	209.7±62.3	0.396
CRP (mg/L)	16.7±11.4	15.8±11.2	0.735
Gender (F/M)	12/32	18/24	0.255
Need of rHuEPO usage for Hb 11-12 g/dL (%)	31	66.7	0.004
rHuEPO dosage (U/kg/week)	204.2 (350.8)	356.4 (295.7)	0.006
rHuEPO/Hb	20.39±19.83	30.71±20.04	0.021